Choosing a depression treatment can be challenging, especially when one medication has not provided enough relief. Two options that work differently are esketamine, the active ingredient in Spravato nasal spray, and selective serotonin reuptake inhibitors (SSRIs), a widely prescribed class of antidepressants. Understanding Esketamine vs. SSRIs can help patients have a more informed conversation with their healthcare provider about their treatment options.
Both approaches aim to reduce depressive symptoms, but they differ in how they work, how they are administered, and the circumstances in which they are considered. The right choice depends on a person's diagnosis, treatment history, health needs, and response to previous medication.
How Do Esketamine and SSRIs Work?
SSRIs, such as sertraline, escitalopram, and fluoxetine, affect serotonin signaling in the brain. Serotonin is involved in mood regulation, among other functions. By reducing its reabsorption between nerve cells, SSRIs increase the availability of serotonin in the spaces where nerve cells communicate.
Esketamine works through a different pathway involving NMDA receptors and the brain's glutamate system. Glutamate is an important neurotransmitter involved in communication between nerve cells. This difference is one reason esketamine may be considered when standard antidepressants have not provided sufficient relief.
However, scientists are still investigating the full range of processes responsible for esketamine's antidepressant effects. Its mechanism should not be viewed as a simple fix for depression or as proof that it is more effective for everyone.
How Quickly Can Each Treatment Work?
SSRIs usually take several weeks to produce noticeable improvements. Some people experience early changes in sleep, appetite, or anxiety, while improvements in mood may take longer. Finding the right medication and dose can also involve adjustments with a prescriber.
Esketamine may produce improvements in depressive symptoms within hours or days for some patients. This relatively rapid response can be valuable for people who have not benefited sufficiently from other treatments. However, not everyone responds, and early improvement does not necessarily mean symptoms will remain controlled without continued care.
A randomized clinical trial published in the American Journal of Psychiatry studied esketamine nasal spray in adults with treatment-resistant depression. Participants receiving esketamine alongside a newly initiated oral antidepressant experienced greater improvement in depressive symptoms over four weeks than those receiving a placebo nasal spray with an oral antidepressant. The findings support esketamine's role as a treatment option, but they do not establish that it is superior to SSRIs for every patient.
When Might a Clinician Consider Each Option?
SSRIs are commonly used as an initial medication treatment for depression. They may be suitable for people experiencing a first depressive episode or those who have not yet tried an antidepressant.
Esketamine is generally considered in more specific clinical circumstances. In the United States, Spravato is approved for adults with treatment-resistant depression, either alone or alongside an oral antidepressant. Treatment-resistant depression generally means that symptoms have not improved adequately after at least two different antidepressant treatments during the current episode.
A clinician may consider factors such as:
Which medications the patient has already tried and how well they worked.
The severity and duration of depressive symptoms.
Other medical conditions and medications.
Previous side effects and individual treatment preferences.
Access to supervised treatment and ongoing follow-up.
Neither option should be selected based on speed alone. A treatment that works well for one person may not be appropriate for another.
What Is Different About Taking the Medication?
SSRIs are usually taken at home according to a prescribed daily schedule. Patients attend follow-up appointments so their clinician can review symptom changes, side effects, and whether the dose needs adjusting.
Spravato follows a different process. The nasal spray is administered under healthcare professional supervision in a certified treatment setting. Patients must remain under observation for at least two hours after each session because of possible side effects, including sedation, dissociation, dizziness, and increased blood pressure. Patients also need to follow restrictions on driving after treatment.
These practical differences matter. Daily medication may fit more easily into some people's routines, while supervised esketamine treatment requires regular appointments and arrangements for transportation.
Can Esketamine and SSRIs Be Used Together?
Yes, depending on the indication and the clinician's treatment plan. Spravato can be prescribed with an oral antidepressant for certain adults with depression. For adults with treatment-resistant depression, US approval also permits Spravato to be used as monotherapy.
The decision to combine treatments depends on the patient's clinical circumstances. Taking more than one medication may introduce additional considerations, so the prescribing clinician should review potential interactions, side effects, and the purpose of each treatment.
People researching depression treatments may encounter personal opinions and medical claims shared through online communities and professional networks, including platforms for sharing information and connecting with other people online. Such discussions can provide different perspectives, but personal experiences cannot establish whether a medication is safe or suitable for a particular individual. Treatment decisions should rely on qualified medical advice and credible clinical evidence.
What About Side Effects and Safety?
SSRIs can cause side effects such as nausea, sleep changes, headaches, and sexual difficulties. Some effects improve over time, but others may persist. Stopping an SSRI suddenly can also cause discontinuation symptoms, so patients should discuss any medication changes with their prescriber.
Esketamine has a different set of risks, including dissociation, sedation, increased blood pressure, and the potential for misuse. It requires supervised administration and monitoring. A clinician will assess relevant medical conditions and other risk factors before recommending treatment.
Neither medication should be considered risk-free. Patients should report troublesome side effects and avoid stopping or changing prescribed medication without professional guidance.
Making an Informed Treatment Decision
Esketamine and SSRIs offer different approaches to treating depression. SSRIs are established medications often used early in treatment, while esketamine provides another option for certain adults, particularly those with treatment-resistant depression.
The most appropriate approach depends on more than the medication itself. Previous treatment response, side effects, medical history, personal preferences, and practical access all matter. A qualified healthcare professional can help weigh these factors and develop a treatment plan that can be reviewed as symptoms change.
The goal is not to choose the newest or fastest-acting option automatically. It is to find a treatment that offers meaningful, sustainable improvement while keeping safety and individual needs at the center of care.
